dc.contributor.author | Nakanishi, Tomoko | |
dc.contributor.author | Martínez Bueno, Manuel | |
dc.contributor.author | García García, Federico | |
dc.contributor.author | Alarcón Riquelme, Marta Eugenia | |
dc.contributor.author | FinnGen | |
dc.contributor.author | The COVID-19 Host Genetics Initiative | |
dc.date.accessioned | 2021-12-23T07:42:12Z | |
dc.date.available | 2021-12-23T07:42:12Z | |
dc.date.issued | 2021-03-12 | |
dc.identifier.citation | Published version: Nakanishi, T... [et al.]. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021;131(23):e152386. [https://doi.org/10.1172/JCI152386] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/72164 | |
dc.description | AG has received support by NordForsk Nordic Trial Alliance (NTA) grant, by Academy of
Finland Fellow grant N. 323116 and the Academy of Finland for PREDICT consortium N.
340541.
The Richards research group is supported by the Canadian Institutes of Health Research
(CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the
Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK,
Genome Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in
Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported
by a research fellowship of the Japan Society for the Promotion of Science for Young
Scientists. GBL is supported by a CIHR scholarship and a joint FRQS and Québec Ministry of
Health and Social Services scholarship. JBR is supported by an FRQS Clinical Research
Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is
funded by the Welcome Trust, the Medical Research Council, the European Union, the
National Institute for Health Research-funded BioResource and the Clinical Research Facility
and Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust in
partnership with King’s College London. The Biobanque Québec COVID19 is funded by FRQS,
Genome Québec and the Public Health Agency of Canada, the McGill Interdisciplinary
Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé. These funding
agencies had no role in the design, implementation or interpretation of this study.
The COVID19-Host(a)ge study received infrastructure support from the DFG Cluster of
Excellence 2167 “Precision Medicine in Chronic Inflammation (PMI)” (DFG Grant: “EXC2167”).
The COVID19-Host(a)ge study was supported by the German Federal Ministry of Education
and Research (BMBF) within the framework of the Computational Life Sciences funding
concept (CompLS grant 031L0165). Genotyping in COVID19-Host(a)ge was supported by a
philantropic donation from Stein Erik Hagen.
The COVID GWAs, Premed COVID-19 study (COVID19-Host(a)ge_3) was supported by
"Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia"and also by
the Instituto de Salud Carlos III (CIBERehd and CIBERER). Funding comes from
COVID-19-GWAS, COVID-PREMED initiatives. Both of them are supported by "Consejeria de
Salud y Familias" of the Andalusian Government. DMM is currently funded by the the
Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018).
The Columbia University Biobank was supported by Columbia University and the National
Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official
views of the NIH or Columbia University.
The SPGRX study was supported by the Consejería de Economía, Conocimiento, Empresas y
Universidad #CV20-10150.
The GEN-COVID study was funded by: the MIUR grant “Dipartimenti di Eccellenza 2018-2020”
to the Department of Medical Biotechnologies University of Siena, Italy; the “Intesa San Paolo
2020 charity fund” dedicated to the project NB/2020/0119; and philanthropic donations to the
Department of Medical Biotechnologies, University of Siena for the COVID-19 host genetics
research project (D.L n.18 of March 17, 2020). Part of this research project is also funded by
Tuscany Region “Bando Ricerca COVID-19 Toscana” grant to the Azienda Ospedaliero
Universitaria Senese (CUP I49C20000280002). Authors are grateful to: the CINECA
consortium for providing computational resources; the Network for Italian Genomes (NIG)
(http://www.nig.cineca.it) for its support; the COVID-19 Host Genetics Initiative
(https://www.covid19hg.org/); the Genetic Biobank of Siena, member of BBMRI-IT, Telethon
Network of Genetic Biobanks (project no. GTB18001), EuroBioBank, and RD-Connect, for
managing specimens.
Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was
supported by Ricerca Corrente (Italian Ministry of Health), intramural funding (Fondazione
Humanitas per la Ricerca). The generous contribution of Banca Intesa San Paolo and of the
Dolce&Gabbana Fashion Firm is gratefully acknowledged.
Data acquisition and sample processing was supported by COVID-19 Biobank, Fondazione
IRCCS Cà Granda Milano; LV group was supported by MyFirst Grant AIRC n.16888, Ricerca
Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, the European Union (EU) Programme Horizon
2020 (under grant agreement No. 777377) for the project LITMUS- “Liver Investigation:
Testing Marker Utility in Steatohepatitis”, Programme “Photonics” under grant agreement
“101016726” for the project “REVEAL: Neuronal microscopy for cell behavioural examination
and manipulation”, Fondazione Patrimonio Ca’ Granda “Liver Bible” PR-0361. DP was
supported by Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
CV PREVITAL “Strategie di prevenzione primaria nella popolazione Italiana” Ministero della
Salute, and Associazione Italiana per la Prevenzione dell’Epatite Virale (COPEV).
Genetic modifiers for COVID-19 related illness (BeLCovid_1) was supported by the "Fonds
Erasme". The Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2)
study was supported by grants from Fondation Léon Fredericq and from Fonds de la
Recherche Scientifique (FNRS).
The INMUNGEN-CoV2 study was funded by the Consejo Superior de Investigaciones
Científicas.
KUL is supported by the German Research Foundation (LU 1944/3-1) SweCovid is funded by the SciLifeLab/KAW national COVID-19 research program project
grant to Michael Hultström (KAW 2020.0182) and the Swedish Research Council to Robert
Frithiof (2014-02569 and 2014-07606). HZ is supported by Jeansson Stiftelser, Magnus
Bergvalls Stiftelse.
The COMRI cohort is funded by Technical University of Munich, Munich, Germany.
Genotyping for the COMRI cohort was performed and funded by the Genotyping Laboratory of
Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki,
Helsinki, Finland.
These funding agencies had no role in the design, implementation or interpretation of this
study. | es_ES |
dc.description.abstract | Background: There is considerable variability in COVID-19 outcomes amongst younger
adults—and some of this variation may be due to genetic predisposition. We characterized the
clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent
effect, using individual-level data in a large international multi-centre consortium.
Method: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by
the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive
patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this
genetic marker with mortality, COVID-19-related complications and laboratory values. We next
examined if the magnitude of these associations varied by age and were independent from
known clinical COVID-19 risk factors.
Findings: We found that rs10490770 risk allele carriers experienced an increased risk of
all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19
related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several
COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6),
venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI
1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure
(OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction
p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory
COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers,
compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes.
Prediction of death or severe respiratory failure among those ≤ 60 years improved when
including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770
risk allele was similar to, or better than, most established clinical risk factors.
Interpretation: The major common COVID-19 risk locus on chromosome 3 is associated with
increased risks of morbidity and mortality—and these are more pronounced amongst individuals
≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk
factors, suggesting potential implications for clinical risk management. | es_ES |
dc.description.sponsorship | Academy of
Finland Fellow grant N. 323116 | es_ES |
dc.description.sponsorship | Academy of Finland for PREDICT consortium N.
340541. | es_ES |
dc.description.sponsorship | Canadian Institutes of Health Research
(CIHR) (365825 and 409511) | es_ES |
dc.description.sponsorship | Lady Davis Institute of the Jewish General Hospital | es_ES |
dc.description.sponsorship | Canadian Foundation for Innovation (CFI) | es_ES |
dc.description.sponsorship | NIH Foundation | es_ES |
dc.description.sponsorship | Cancer Research UK | es_ES |
dc.description.sponsorship | Genome Québec | es_ES |
dc.description.sponsorship | Public Health Agency of Canada | es_ES |
dc.description.sponsorship | McGill Interdisciplinary Initiative in
Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS) | es_ES |
dc.description.sponsorship | Japan Society for the Promotion of Science for Young
Scientists | es_ES |
dc.description.sponsorship | CIHR scholarship and a joint FRQS and Québec Ministry of
Health and Social Services scholarship | es_ES |
dc.description.sponsorship | FRQS Clinical Research
Scholarship | es_ES |
dc.description.sponsorship | Calcul Québec | es_ES |
dc.description.sponsorship | Compute Canada | es_ES |
dc.description.sponsorship | Welcome Trust | es_ES |
dc.description.sponsorship | Medical Research Counc | es_ES |
dc.description.sponsorship | European Union | es_ES |
dc.description.sponsorship | National Institute for Health Research-funded BioResource | es_ES |
dc.description.sponsorship | Clinical Research Facility
and Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust | es_ES |
dc.description.sponsorship | King’s College London | es_ES |
dc.description.sponsorship | Genome Québec | es_ES |
dc.description.sponsorship | Public Health Agency of Canada | es_ES |
dc.description.sponsorship | McGill Interdisciplinary
Initiative in Infection and Immunity | es_ES |
dc.description.sponsorship | Fonds de Recherche Québec Santé | es_ES |
dc.description.sponsorship | (DFG Grant: “EXC2167”) | es_ES |
dc.description.sponsorship | (CompLS grant 031L0165) | es_ES |
dc.description.sponsorship | Stein Erik Hagen | es_ES |
dc.description.sponsorship | "Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia" | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III (CIBERehd and CIBERER) | es_ES |
dc.description.sponsorship | COVID-19-GWAS | es_ES |
dc.description.sponsorship | COVID-PREMED initiatives | es_ES |
dc.description.sponsorship | "Consejeria de
Salud y Familias" of the Andalusian Government | es_ES |
dc.description.sponsorship | Andalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018) | es_ES |
dc.description.sponsorship | Columbia University | es_ES |
dc.description.sponsorship | National
Center for Advancing Translational Sciences | es_ES |
dc.description.sponsorship | NIH Grant Number UL1TR001873 | es_ES |
dc.description.sponsorship | Consejería de Economía, Conocimiento, Empresas y
Universidad #CV20-10150 | es_ES |
dc.description.sponsorship | MIUR grant “Dipartimenti di Eccellenza 2018-2020” | es_ES |
dc.description.sponsorship | “Intesa San Paolo
2020 charity fund” dedicated to the project NB/2020/0119 | es_ES |
dc.description.sponsorship | Tuscany Region “Bando Ricerca COVID-19 Toscana” | es_ES |
dc.description.sponsorship | CINECA
consortium | es_ES |
dc.description.sponsorship | Network for Italian Genomes (NIG) | es_ES |
dc.description.sponsorship | COVID-19 Host Genetics Initiative | es_ES |
dc.description.sponsorship | Genetic Biobank of Siena | es_ES |
dc.description.sponsorship | EuroBioBank | es_ES |
dc.description.sponsorship | RD-Connect | es_ES |
dc.description.sponsorship | Ricerca Corrente (Italian Ministry of Health) | es_ES |
dc.description.sponsorship | Fondazione
Humanitas per la Ricerca | es_ES |
dc.description.sponsorship | Banca Intesa San Paolo | es_ES |
dc.description.sponsorship | Dolce&Gabbana Fashion Firm | es_ES |
dc.description.sponsorship | COVID-19 Biobank | es_ES |
dc.description.sponsorship | Fondazione
IRCCS Cà Granda Milano | es_ES |
dc.description.sponsorship | MyFirst Grant AIRC n.16888 | es_ES |
dc.description.sponsorship | Ricerca
Finalizzata Ministero della Salute RF-2016-02364358 | es_ES |
dc.description.sponsorship | Ricerca corrente Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico | es_ES |
dc.description.sponsorship | European Union (EU) Programme Horizon
2020 (under grant agreement No. 777377) | es_ES |
dc.description.sponsorship | “Photonics” “101016726” | es_ES |
dc.description.sponsorship | Fondazione Patrimonio Ca’ Granda “Liver Bible” PR-0361 | es_ES |
dc.description.sponsorship | CV PREVITAL “Strategie di prevenzione primaria nella popolazione Italiana” Ministero della
Salute, and Associazione Italiana per la Prevenzione dell’Epatite Virale (COPEV) | es_ES |
dc.description.sponsorship | "Fonds
Erasme" | es_ES |
dc.description.sponsorship | Fondation Léon Fredericq | es_ES |
dc.description.sponsorship | Fonds de la
Recherche Scientifique (FNRS) | es_ES |
dc.description.sponsorship | Consejo Superior de Investigaciones
Científicas | es_ES |
dc.description.sponsorship | German Research Foundation (LU 1944/3-1) | es_ES |
dc.description.sponsorship | SciLifeLab/KAW national COVID-19 research program project (KAW 2020.0182) | es_ES |
dc.description.sponsorship | Swedish Research Council (2014-02569 and 2014-07606) | es_ES |
dc.description.sponsorship | Jeansson Stiftelser, Magnus
Bergvalls Stiftelse | es_ES |
dc.description.sponsorship | Technical University of Munich, Munich, Germany | es_ES |
dc.description.sponsorship | Genotyping Laboratory of
Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki,
Helsinki, Finland | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Society for Clinical Investigation | es_ES |
dc.rights | Atribución 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.title | Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality | es_ES |
dc.type | journal article | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/777377 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.1101/2021.03.07.21252875 | |
dc.type.hasVersion | SMUR | es_ES |